Multiple Myeloma: Risk adapted use of plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient

Background: We used plerixafor in ‘a risk adapted approach’ for stem cell mobilization for multiple myeloma (MM) patients prior to autologous stem cell transplantation (ASCT).Patients and Methods: Between January, 2017 and December, 2019 one hundred and five consecutive patients of MM were recruited (Study Cohort). Patients rece ived inj G-CSF 10 µg/kg in 2 divided doses for 5 days. Day 4 peripheral blood (PB) CD34+ count was used as a guide; if count was

Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Vadlamani Surya Prakash, Prabhat Singh Malik, Ranjit Kumar Sahoo, Raja Pramanik, Priyanshu Choudhary, Ankur Nandan Varshney, Lalit Kumar Source Type: research